drugset / Trial / NCT05592379
Consciousness, Psilocybin, and Well-Being
Phase 1
Completed
6 enrolled
University of Wisconsin, Madison
Tiny Blue Dot Foundation · collabUsona Institute · collab
Non-randomizedSequentialSingle-blindBasic science
Summary
This study is being done to identify a dosing strategy that will allow IV psilocybin to be administered to sleeping participants without awakening them.
Timeline
- Start
- 2023-11-07
- Primary completion
- 2025-02-19
- Completion
- 2025-02-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Clonidine | Other / unclassified | 0.2 mg | Oral |
| Subject | Psilocybin | Other / unclassified | 2 mg | Intravenous |
Indications
No indication recorded.